Form 4: Inhibrx Biosciences CEO Buys Shares
Insider Transaction (Form 4)
Mark Lappe, Chief Executive Officer and a Director of Inhibrx Biosciences, Inc., purchased 10,040 shares of common stock on October 14, 2026.
Summary
- Open-market purchase: acquired 2,470 Common Stock at $84.07 ($207,655) on October 14, 2026; holds 743,018 after (Indirect).
- Open-market purchase: acquired 2,470 Common Stock at $85.00 ($209,948) on October 14, 2026; holds 745,488 after (Indirect).
- Open-market purchase: acquired 100 Common Stock at $85.76 ($8,576) on October 14, 2026; holds 745,588 after (Indirect).
- Open-market purchase: acquired 2,449 Common Stock at $84.07 ($205,889) on October 14, 2026; holds 167,449 after (Indirect).
- Open-market purchase: acquired 2,451 Common Stock at $85.00 ($208,333) on October 14, 2026; holds 169,900 after (Indirect).
- Open-market purchase: acquired 100 Common Stock at $85.76 ($8,576) on October 14, 2026; holds 170,000 after (Indirect).
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $848,977, committing personal capital to the stock.
Insider Transactions
Mark Lappe — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Open-market purchase | Common Stock | 2,470 | $84 | $207.7K | 743,018 |
| 2026-10-14 | Open-market purchase | Common Stock | 2,470 | $85 | $209.9K | 745,488 |
| 2026-10-14 | Open-market purchase | Common Stock | 100 | $86 | $8.6K | 745,588 |
| 2026-10-14 | Open-market purchase | Common Stock | 2,449 | $84 | $205.9K | 167,449 |
| 2026-10-14 | Open-market purchase | Common Stock | 2,451 | $85 | $208.3K | 169,900 |
| 2026-10-14 | Open-market purchase | Common Stock | 100 | $86 | $8.6K | 170,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Open-market purchase (2,470 shares) |
| 2026-10-14 | Open-market purchase (2,470 shares) |
| 2026-10-14 | Open-market purchase (100 shares) |
| 2026-10-14 | Open-market purchase (2,449 shares) |
| 2026-10-14 | Open-market purchase (2,451 shares) |
| 2026-10-14 | Open-market purchase (100 shares) |
Keywords
insider transaction, Form 4, INBX, Inhibrx Biosciences, Inc., bullish, Mark Lappe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.